



Transforming the Fight Against Cancer

Not theoretical. Not someday. Today.

Nuclear Innovation for the Next Generation of Isotopes


One in three people¹ will be diagnosed with cancer in their lifetime, and with cancer comes uncertainty. The world doesn't need more hypotheticals. It needs results.

Today, TerraPower Isotopes is engineering, testing, and delivering those results. The TPI® team is advancing a new class of nuclear technologies to support the global pharmaceutical community in developing and expanding access to a diverse suite of targeted cancer treatments. This work is made possible by producing commercial-scale quantities of actinium-225 through a unique public-private partnership.



TERRAPOWER ISOTOPES AIMS TO INCREASE THE GLOBAL SUPPLY OF Ac-225 BY

75 – 100x



Actinium-225 Is Different

Actinium-225 is an alpha-emitting radionuclide that can be used by pharmaceutical companies developing targeted alpha therapies for cancer patients. Through further manufacturing, the isotope can be attached to an active molecule for targeted delivery to the cancer site. When injected, actinium-225 labeled drug products, when developed and approved, will be able to destroy the cancerous tissues with minimum damage to nearby healthy cells, leading to effective and targeted therapy treatments.

Access to actinium-225 has been the key limitation to research and drug development. TPI is changing that.

FROM RESEARCH TO REALITY

How TerraPower Isotopes Delivers

TerraPower Isotopes solves challenges that can't be answered by traditional approaches. TPI applies proven development methods, public-private partnerships, and innovative nuclear science to provide research grade actinium-225 to pharmaceutical companies.



Recover

In partnership with Isotek and the U.S. Dept. of Energy, thorium-229, the source of actinium-225, is acquired from legacy nuclear materials, reducing cleanup times and cost while advancing nuclear science.



Extract

TPI uses natural decay methods with advanced radioisotope generators to increase the efficiency and automation in harvesting research grade actinium-225.



Supply

TPI supplies the pharmaceutical industry with isotopic starting materials that are further manufactured for targeted alpha therapy research and development.



Impact

In 2024, TPI began providing actinium-225 to drug developers for use in human clinical trials. In 2026, TPI starts construction on a cGMP facility to increase actinium-225 production.



Transformative solutions move the world forward—the proof is in our progress.

TerraPower Isotopes is advancing new medical applications to enable potentially lifesaving cancer therapies. We're not just a nuclear developer, we're an innovation driver, relentlessly focused on results.

Transform health. Explore impact.

[TerraPower.com](https://www.terrapower.com)